Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

ACORDA THERAPEUTICS INC (ACOR)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Acorda Therapeutics Inc : Acorda Presents New Data on Diazepam Nasal Spray at 67th Annual Meeting of American Epilepsy Society

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/09/2013 | 01:01pm CEST

Study found Diazepam Nasal Spray maintained consistent pharmacokinetic profile when administered during or immediately after seizure

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that new data from a pharmacokinetics study on Diazepam Nasal Spray found comparable pharmacokinetics (PK) whether the drug was administered during or immediately after a seizure. These data were presented at the 67th Annual Meeting of the American Epilepsy Society, in Washington, D.C. Diazepam Nasal Spray is being developed for the treatment of people with epilepsy who experience cluster seizures, also known as acute repetitive seizures.

"In this study, some patients received a dose of Diazepam Nasal Spray while having a seizure, while others received the dose after their seizure activity had ceased," said Adrian Rabinowicz, M.D., FAAN, Acorda's Senior Vice President of Clinical Development and Medical Affairs. "The results suggest that delivery of Diazepam Nasal Spray was unaffected by the timing of dosage relative to seizure activity. It is critical for a person with epilepsy who experiences cluster seizures that treatment be administered as soon as possible after a cluster is recognized, in order to prevent additional seizure activity."

This multicenter, open-label study was conducted in adults admitted to an epilepsy monitoring unit for evaluation and management of epilepsy. Of the 30 patients who completed the study, 10 were dosed during a seizure, while the other 20 patients were dosed after their seizure activity had ceased. Plasma concentrations of diazepam were measured for a period of up to 12 hours following the dose.

The overall safety and tolerability of Diazepam Nasal Spray in this study was consistent with systemic diazepam exposure established with other diazepam products. The most common local adverse events were related to the nasal route of delivery; most adverse events were mild and transient, and resolved within a day. These local events were an altered sense of taste and nasal discomfort, experienced by 26% and 23% of study subjects respectively.

Other data from this study were previously presented at the 30th biennial International Congress of the International League Against Epilepsy and International Bureau for Epilepsy.

Acorda has submitted a New Drug Application for Diazepam Nasal Spray to the U.S. Food and Drug Administration (FDA) and will rely upon the FDA's previous findings of safety and efficacy for diazepam rectal gel.

About Epilepsy and Cluster Seizures/Acute Repetitive Seizures

Epilepsy is a neurological condition that produces seizures affecting a variety of mental and physical functions. Seizures are symptoms of abnormal brain activity, and occur when a brief, strong surge of electrical activity affects part or all of the brain.

Of the approximately 2.75 million people in the United States with epilepsy, it is estimated that about 175,000 experience cluster seizures. Cluster seizures, also known as acute repetitive seizures, are characterized by recognizable, recurring episodes of seizure clusters.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological conditions.

Acorda markets three FDA-approved therapies including: AMPYRA®(dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.

Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure. For more information, please visit the Company's website at: www.acorda.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including Diazepam Nasal Spray or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market Diazepam Nasal Spray or other products under development; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen Idec in connection therewith; competition, including the impact of generic competition on Zanaflex Capsules revenues; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; failure to comply with regulatory requirements could result in adverse action by regulatory agencies; and the ability to obtain additional financing to support our operations. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities & Exchange Commission. Acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and Acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.

Acorda Therapeutics
Jeff Macdonald, 914-326-5232
[email protected]


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACORDA THERAPEUTICS INC
04/16ACORDA THERAPEUTICS : to Present New Data For INBRIJA™ (levodopa inhalatio..
BU
04/11ACORDA FIRST QUARTER UPDATE : Webcast/Conference Call Scheduled for May 2, 2018
BU
03/26ACORDA THERAPEUTICS,INC. (NASDAQ : ACOR) Files An 8-K Other Events
AQ
03/26ACORDA THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form ..
AQ
03/22ACORDA THERAPEUTICS : to Present at Oppenheimer Healthcare Conference
AQ
03/19ACORDA THERAPEUTICS : 420 Saw Mill River Rd. Ardsley, NY 10502
AQ
03/19ACORDA THERAPEUTICS : 65-- Acorda Therapeutics, Inc. 420 Saw Mill River Rd. Ards..
AQ
03/17ACORDA THERAPEUTICS : $97.35 Million Federal Contract Awarded to Acorda Therapeu..
AQ
03/15ACORDA THERAPEUTICS : to Present at Cowen Health Care Conference
AQ
03/14ACORDA THERAPEUTICS : Rallies Parkinson’s Community in First-of-Its-Kind I..
BU
More news
News from SeekingAlpha
04/19INSTITUTIONAL TOP IDEAS SERIES : Scopia Capital 
03/29Looking For Action? S&P 1500 Most Volatile Stocks 
03/26Acorda files marketing application in Europe for Parkinson's med Inbrija; sha.. 
03/16Key events next week - healthcare (continued #1) 
03/09Key events next week - healthcare (continued #3) 
Financials ($)
Sales 2018 370 M
EBIT 2018 23,2 M
Net income 2018 -44,6 M
Debt 2018 274 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 3,70x
EV / Sales 2019 8,14x
Capitalization 1 095 M
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Technical analysis trends ACORDA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 25,5 $
Spread / Average Target 9,2%
EPS Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
Andrew R. Blight Chief Scientific Officer
Richard P. Batycky Chief Technology Officer
Burkhard Blank Chief Medical Officer
Sandra Panem Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS INC9.09%1 095
GILEAD SCIENCES3.91%96 094
VERTEX PHARMACEUTICALS6.47%40 153
REGENERON PHARMACEUTICALS-15.99%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998